Silence Therapeutics GmbH   Report issue

For profit Phase 2
Founded: London United Kingdom (1999)

Organization Overview

First Clinical Trial
2009
NCT00938574
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Silence Therapeutics | Silence Therapeutics plc

Active Ingredients

Drugs in Phase 2 Trials (4)

atu027 (2 trials)

gemcitabine (gemzar) (1 trial)

sln124 (4 trials)

sln360 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

beta-Thalassemia (Phase 1)

Carcinoma, Pancreatic Ductal (Phase 2)

Dyslipidemias (Phase 1)

Hyperlipidemias (Phase 1)

Hyperlipoproteinemias (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Preleukemia (Phase 1)

Syndrome (Phase 1)

Thalassemia (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 4